Vir Biotechnology Inc VIR.OQ VIR.O is expected to show a fall in quarterly revenue when it reports results on November 5 for the period ending September 30 2025
The San Francisco California-based company is expected to report a 16.7% decrease in revenue to $1.983 million from $2.38 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Vir Biotechnology Inc is for a loss of 85 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vir Biotechnology Inc is $15.00, about 60.3% above its last closing price of $5.96
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.73 | -0.72 | -0.80 | Missed | -10.6 |
Mar. 31 2025 | -0.82 | -0.84 | -0.88 | Missed | -5.3 |
Dec. 31 2024 | -0.87 | -0.87 | -0.76 | Beat | 12.9 |
Sep. 30 2024 | -1.07 | -1.05 | -1.56 | Missed | -48.2 |
Jun. 30 2024 | -0.88 | -0.90 | -1.02 | Missed | -13.9 |
Mar. 31 2024 | -1.06 | -1.05 | -0.48 | Beat | 54.3 |
Dec. 31 2023 | -1.11 | -1.01 | -0.86 | Beat | 14.7 |
Sep. 30 2023 | -1.25 | -1.21 | -1.22 | Missed | -1.2 |
This summary was machine generated November 3 at 21:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)